Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

KRYŠTOF Vladimír ULDRIJAN Stjepan

Year of publication 2010
Type Article in Periodical
Magazine / Source Current Drug Targets
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords CDK; protein kinase; inhibitor; therapy; oncology; resistance; p53; DNA damage
Description Poor therapeutic outcomes and serious side effects, together with acquired resistance to multiple drugs, are common problems of current cancer therapies. Therefore, there is an urgent need for new cancer-targeted drugs, which has led (inter alia) to the development of molecules that can specifically inhibit cyclin-dependent kinases (CDKs). In addition to their cell cycle regulatory functions, CDKs, especially CDK7 and CDK9, play important roles in the regulation of RNA polymerase II-mediated transcription. Here, we report on progress in the preclinical development of CDK inhibitors and their anticancer activities. Special attention is paid to the action mechanisms of the pan-specific CDK inhibitors flavopiridol and roscovitine, which have already entered phase II clinical trials as treatments for various tumours.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.